SAB Biotherapeutics has dosed the first patient in SAFEGUARD, a Phase 2b registrational study evaluating SAB-142, a fully human anti-thymocyte globulin, in stage 3 (new-onset) type 1 diabetes. The global, multicenter program features a two-infusion regimen separated by 6 months, followed by a 12-month extension. Part A is an adult dose-ranging study; Part B is a randomized, double-blind, placebo-controlled study. Enrollment is active in the U.S., Australia, and New Zealand, with European sites to follow. The company guides to Phase 2b data in the second half of 2027.
At its core, this is a bet that the clinical logic of rabbit ATG—which has repeatedly shown beta-cell preservation signals in new-onset T1D—can be reproduced and potentially improved with a fully human, redosable product. Labeling the trial “registrational” signals an intent to compress the path to approval if the magnitude and durability of C-peptide and glycemic endpoints are strong. It also puts manufacturing and regulatory scrutiny front and center: SAB-142 is produced via transchromosomic cattle, yielding polyclonal, fully human IgG, a distinctive CMC profile that must demonstrate lot-to-lot consistency, pathogen safety, and robust potency assays. The company references Phase 1 safety, immunogenicity, and pharmacodynamic data presented earlier this year, but without quantitative detail, the burden shifts to this mid-stage program to validate tolerability, re-dosing feasibility, and mechanistic biomarkers relative to legacy ATG.
Operationally, this trial sits at the intersection of endocrinology and immunology workflows, which have historically been siloed. Sites will need to execute rapid referral and screening to capture the narrow post-diagnosis window, deliver infusion-based immunotherapy with premedication and monitoring, and standardize mixed-meal tolerance tests and central lab workflows to support C-peptide endpoints. The two-infusion schedule eases logistics compared to prolonged dosing regimens, but still requires infusion capacity and AE management familiar to transplant and oncology units. The placebo-controlled design aligns with the insulin-based standard of care. Still, it avoids a head-to-head comparison with rabbit ATG, which may be a discussion point for clinicians and regulators. For CROs and vendors, the study favors networks with access to new-onset T1D pipelines, pediatric transition strategies, and high-fidelity biomarker collection. At the same time, the long-term extension heightens data continuity and retention demands.
Strategically, SAB is pursuing the gap left by teplizumab’s approval in stage 2 by targeting the larger stage 3 population, where disease modification remains largely experimental. FDA has been clear that preservation of stimulated C-peptide at 12 months is necessary but not sufficient; alignment on glycemic outcomes, insulin requirements, and hypoglycemia metrics will be critical, as will subgroup performance across age bands. Safety will determine real-world uptake: a less immunogenic, fully human ATG could enable re-dosing and broader use, but any signal of infusion reactions, prolonged lymphocyte depletion, or infection risk will narrow the addressable setting. Manufacturing scale and regulatory familiarity with the bovine-derived production platform remain gating factors for global filings.
The immediate watch items are enrollment velocity in a time-sensitive diagnosis setting, the inclusion timeline for adolescents, and the final statistical architecture and endpoint hierarchy in Part B. Biomarker depth—particularly T-cell phenotyping and cytokine dynamics—will help contextualize efficacy and de-risk comparisons to rabbit ATG. On the CMC front, consistency packages and viral safety validations are likely to draw early agency attention. With data not expected until 2H 2027, interim operational read-throughs may come from site activations and geographic spread. If the signal matches or exceeds historical ATG effects with a cleaner safety and re-dosing profile, sponsors and sites should anticipate an operational shift toward immunomodulatory interventions in routine T1D care; if not, the case for polyclonal, large-molecule immunotherapy in autoimmunity will face renewed skepticism.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
